Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vancomycin Study in Multiple Sclerosis (MS)
Sponsor: Icahn School of Medicine at Mount Sinai
Summary
The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.
Official title: Impact of Vancomycin on the Gut Microbiome and Immune Function in Multiple Sclerosis
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2023-01-31
Completion Date
2026-09
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
Vancomycin
A marketed antibiotic (Study Drug) supplied by Amerisource Bergen, by the Mount Sinai Investigational Drug Services (IDS), and encapsulated in red coating to match the placebo.
Placebo
Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
Locations (1)
Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai
New York, New York, United States